Artiva Biotherapeutics, Inc. (ARTV) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$26.20M*; Operating income -$26.89M; Depreciation and amortization $692.00K*.
- 2026-03-31: Basis Reported; EBITDA -$23.76M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$21.27M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$22.23M*; Operating income -$22.90M; Depreciation and amortization $662.00K*.
Complete source-backed ebitda history.
- Available history
- 2023-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$26.20M* | -$26.89M | $692.00K* | (m) | (m) | $415.00K* | -$20.36M* | (m) | $21.93M | (m) | (m) |
|---|
| 2026-03-31 | Reported | -$23.76M | (m) | (m) | (m) | (m) | $242.00K | -$20.95M | (m) | $19.31M | (m) | (m) |
|---|
| 2025-12-31 | Reported | -$21.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$22.23M* | -$22.90M | $662.00K* | (m) | (m) | $600.00K* | -$19.20M* | (m) | $17.63M | (m) | (m) |
|---|
| 2025-06-30 | Reported | -$22.17M* | -$22.81M | $641.00K* | (m) | (m) | $1.05M* | -$22.98M* | (m) | $17.86M | (m) | (m) |
|---|
| 2025-03-31 | Reported | -$21.54M | (m) | (m) | (m) | (m) | $511.00K | -$19.84M | (m) | $17.05M | (m) | (m) |
|---|
| 2024-12-31 | Reported | -$17.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$17.71M* | -$18.34M | $627.00K* | (m) | (m) | $96.00K* | -$11.61M* | (m) | $13.52M | (m) | (m) |
|---|
| 2024-06-30 | Reported | -$15.59M* | -$16.19M | $603.00K* | (m) | (m) | $464.00K* | -$13.69M* | (m) | $12.33M | (m) | (m) |
|---|
| 2024-03-31 | Reported | -$13.91M | (m) | (m) | (m) | -5539.84% | $18.00K | -$15.09M | (m) | $11.16M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$11.38M | (m) | (m) | (m) | -638.74% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | $11.37M* | $10.81M | $556.00K* | $26.66M | 42.64%* | $179.00K* | -$10.75M* | (m) | $13.06M | (m) | (m) |
|---|
| 2023-06-30 | Reported | (m) | -$11.82M | (m) | $3.50M | (m) | (m) | (m) | (m) | $11.26M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$87.21M | (m) | (m) | (m) | (m) | $2.59M | -$76.75M | (m) | $69.54M | (m) | $0.00 |
|---|
| 2024-12-31 | Reported | -$64.85M | (m) | (m) | (m) | -25837.05% | $642.00K | -$55.03M | (m) | $50.33M | (m) | $0.00 |
|---|
| 2023-12-31 | Reported | -$28.41M | (m) | (m) | (m) | -86.28% | $3.26M | -$47.43M | (m) | $50.25M | (m) | $72.00K |
|---|